Form 4: Compass Therapeutics Director Philip Ferneau Acquires 40,000 Stock Options

Director Philip Ferneau acquired 40,000 stock options in Compass Therapeutics, Inc. on February 11, 2025.

Summary

• On February 11, 2025, Philip Ferneau, a director of Compass Therapeutics, Inc., acquired 40,000 stock options.
• The exercise price of these options is $3.65.
• The options vest over 48 months, starting March 11, 2025.
• The options expire on February 11, 2035.
• Following the transaction, Ferneau directly owns 40,000 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock option grants, which can be seen as a positive sign of alignment between management and shareholders, but doesn't necessarily indicate a major shift in the company's prospects.

Positives

• The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This is a standard SEC Form 4 filing, reflecting a change in beneficial ownership of securities. It's common for directors and officers to receive stock options as part of their compensation.

Stakeholder Impact

• The granting of stock options aligns the director's interests with those of the shareholders, potentially incentivizing actions that increase shareholder value.

Key Dates